Abstract
Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Current Alzheimer Research
Title: Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Volume: 5 Issue: 5
Author(s): James G. McLarnon and Jae K. Ryu
Affiliation:
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Abstract: Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Export Options
About this article
Cite this article as:
McLarnon G. James and Ryu K. Jae, Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain, Current Alzheimer Research 2008; 5 (5) . https://dx.doi.org/10.2174/156720508785908874
DOI https://dx.doi.org/10.2174/156720508785908874 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Physical Activity Level and Motor Aptitude: Motor Domains and Identification Capacity of Brazilian Insufficiently Active Older Adults
Current Aging Science All for Statins and Statins for All; An Update
Current Pharmaceutical Design REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular
Current Neuropharmacology Onset Age and Clinical Heterogeneity of Dementias: A Diagnostic and Therapeutic Approach
Current Psychopharmacology Development of Subjective Cognitive Decline
Neuroscience and Biomedical Engineering (Discontinued) Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Editorial Review 2015
Current Radiopharmaceuticals The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times
Current Neuropharmacology Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary)
Current Alzheimer Research Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry